...
search icon
nuvl-img

Nuvalent Inc Share Price

NUVL
NSQ
$102.24
+$1.42
(1.41%)
1D
Industry: Biotechnology Sector: Health Care

Nuvalent Inc Analyst Forecast

Nuvalent Inc Share Price Chart

Nuvalent Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.83B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
485.27K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$55.53 L
$113.02 H
$102.24

About Nuvalent Inc, Common Stock

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Nuvalent Inc Stock Returns

Time FrameNUVLSectorS&P500
1-Week Return0.16%1.51%-1.5%
1-Month Return-3.48%1.46%0.6%
3-Month Return-5.33%3.94%2.43%
6-Month Return36.3%16.03%6.01%
1-Year Return29.11%9.1%11.48%
3-Year Return214.29%19.46%67.52%
5-Year Return445.28%35.29%73.75%

Nuvalent Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses16.91M45.82M86.11M149.49M280.37M[{"date":"2020-12-31","value":6.03,"profit":true},{"date":"2021-12-31","value":16.34,"profit":true},{"date":"2022-12-31","value":30.71,"profit":true},{"date":"2023-12-31","value":53.32,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(16.91M)(45.82M)(86.11M)(149.49M)(280.37M)[{"date":"2020-12-31","value":-1690500000,"profit":false},{"date":"2021-12-31","value":-4581700000,"profit":false},{"date":"2022-12-31","value":-8610800000,"profit":false},{"date":"2023-12-31","value":-14949200000,"profit":false},{"date":"2024-12-31","value":-28036800000,"profit":false}]
Total Non-Operating Income/Expense--8.51M46.55M58.69M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":14.5,"profit":true},{"date":"2023-12-31","value":79.31,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(14.56M)(46.34M)(81.85M)(126.22M)(259.99M)[{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-8185400000,"profit":false},{"date":"2023-12-31","value":-12621900000,"profit":false},{"date":"2024-12-31","value":-25999200000,"profit":false}]
Income Taxes(2.35M)521.00K(8.51M)(167.90K)764.00K[{"date":"2020-12-31","value":-307.46,"profit":false},{"date":"2021-12-31","value":68.19,"profit":true},{"date":"2022-12-31","value":-1113.61,"profit":false},{"date":"2023-12-31","value":-21.98,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes--(73.35M)(126.05M)(260.76M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-7334600000,"profit":false},{"date":"2023-12-31","value":-12605110500,"profit":false},{"date":"2024-12-31","value":-26075600000,"profit":false}]
Income From Continuous Operations(14.56M)(46.34M)(81.85M)(114.05M)(260.76M)[{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-8185400000,"profit":false},{"date":"2023-12-31","value":-11405000000,"profit":false},{"date":"2024-12-31","value":-26075600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(14.56M)(46.34M)(73.35M)(126.22M)(260.76M)[{"date":"2020-12-31","value":-1455600000,"profit":false},{"date":"2021-12-31","value":-4633800000,"profit":false},{"date":"2022-12-31","value":-7334600000,"profit":false},{"date":"2023-12-31","value":-12621900000,"profit":false},{"date":"2024-12-31","value":-26075600000,"profit":false}]
EPS (Diluted)(2.39)(4.33)(1.64)(2.16)(3.90)[{"date":"2020-12-31","value":-238.74,"profit":false},{"date":"2021-12-31","value":-433,"profit":false},{"date":"2022-12-31","value":-164,"profit":false},{"date":"2023-12-31","value":-216,"profit":false},{"date":"2024-12-31","value":-390,"profit":false}]

Nuvalent Inc Ratios

Nuvalent Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

NUVL
Cash Ratio 10.58
Current Ratio 10.73

Nuvalent Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NUVL
ROA (LTM) -22.96%
ROE (LTM) -38.79%

Nuvalent Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NUVL
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Nuvalent Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NUVL
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 9.26
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Nuvalent Inc share price today?

Nuvalent Inc (NUVL) share price today is $102.24

Can Indians buy Nuvalent Inc shares?

Yes, Indians can buy shares of Nuvalent Inc (NUVL) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NUVL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nuvalent Inc be purchased?

Yes, you can purchase fractional shares of Nuvalent Inc (NUVL) via the Vested app. You can start investing in Nuvalent Inc (NUVL) with a minimum investment of $1.

How to invest in Nuvalent Inc shares from India?

You can invest in shares of Nuvalent Inc (NUVL) via Vested in three simple steps:

  • Click on Sign Up or Invest in NUVL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nuvalent Inc shares
What is Nuvalent Inc 52-week high and low stock price?

The 52-week high price of Nuvalent Inc (NUVL) is $113.02. The 52-week low price of Nuvalent Inc (NUVL) is $55.53.

What is Nuvalent Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Nuvalent Inc (NUVL) is

What is Nuvalent Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nuvalent Inc (NUVL) is 9.26

What is Nuvalent Inc dividend yield?

The dividend yield of Nuvalent Inc (NUVL) is 0.00%

What is the Market Cap of Nuvalent Inc?

The market capitalization of Nuvalent Inc (NUVL) is $7.83B

What is Nuvalent Inc's stock symbol?

The stock symbol (or ticker) of Nuvalent Inc is NUVL

How Can Investors Use Nuvalent Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Nuvalent Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Nuvalent Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Nuvalent Inc shares for Indian investors?

When investing in Nuvalent Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Nuvalent Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Nuvalent Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Nuvalent Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Nuvalent Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top